Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

Mullens W. NEJM 2022; 387:1185 – 1195. doi:10.1056/NEJMoa2203094

Clinical Question

  • In adult patients with acute decompensated heart failure (ADHF), does the addition of acetazolamide to loop diuretics improve decongestion by day 3?

Background

  • Fluid overload has been independently shown to increase mortality in the general ICU population
  • A recent registry study of nearly 50,000 ICU admissions reported that around half of all ICU patients are administered diuretics during their stay – in 95% of instances patients receive furosemide
  • The ASCEND-HF trial showed that a high proportion of patients with ADHF were admitted to a critical care area (ICU or CCU) and re-admission rates are high (50% within 6 months)
  • Readmission is associated with increased morbidity and mortality, however optimal strategies for decongestion are yet to be determined

What did they do?

  • Between 2018 and 2022, 519 adult patients admitted to hospital with ADHF and clinical signs of fluid overload alongside a raised BNP were randomised
  • Important exclusion criteria included current use of acetazolamide or an SGLT2 inhibitor, hypotension (SBP < 90 mmHg), a GFR < 20 ml /min
  • Treatment with IV furosemide > 80 mg (or equivalent) during index hospitalization was not allowed prior to randomisation
  • Patients were randomised in 1:1 ratio to receive either 500mg dose of acetazolamide or matching placebo
    • This was given for 3 days or until complete decongestion (clinical absence of fluid overload (oedema, pleural effusions and ascites)
  • Loop diuretics were given at double maintenance dose (as a bolus and then split into two doses per day for the next 2 days)
    • Median daily maintenance dose of furosemide was 60mg across all groups
  • Treatment could be escalated according to a protocol if urine output insufficient and ongoing evidence of fluid overload
  • Baseline characteristics were balanced between groups

What did it show?

  • ┬áIncreased rates of successful decongestion in acetazolamide group (RR 1.46, 95% CI 1.17 – 1.82)
  • This seemed to persist to hospital discharge in an exploratory analysis
  • Increased diuresis (500mls at 48 hours, 95% CI 200 to 800mls) and natriuresis on day 2 in acetazolamide group
  • No difference in mortality or length of hospital stay
  • No difference in adverse events

How does it fit into other evidence?

  • The DOSE trial was a 2×2 factorial trial that randomized patients with acute decompensated heart failure (ADHF) to a high or low dose furosemide strategy as either a bolus or continuous infusion
  • No significant difference in patient’s perceived symptoms or renal function was noted between the groups, however across all groups only ~15% were free from congestion at 72 hours
  • This study shows that decongestion can be improved with the addition of acetazolamide, however, benefit with respect to patient focused outcomes have yet to be shown
  • Ultrafiltration as a strategy to decongest ADHF patients has also been studied (UNLOAD, CARESS-HF) with differing results with respect to success of decongestion and hospital readmissions

External Links

Metadata

Summary author: George Walker
Summary date: 30th May 2023

Picture by: fietzfotos/Pixabay

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.